readthroughSign in
Nov 16, 2026Trial update

Pemigatinib bladder cancer trial posts results; study remains active not recruiting

A Phase 2 window-of-opportunity study testing pemigatinib in recurrent NMIBC patients posted results after reaching primary completion.

One update this week concerns a Johns Hopkins-sponsored trial of Incyte's pemigatinib in bladder cancer.

  • This Phase 2 trial tests pemigatinib, an oral inhibitor of fibroblast growth factor receptors 1, 2, and 3, in non-muscle invasive bladder cancer patients with recurrent tumors and a prior history of low- or intermediate-risk disease.1 The study is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with Incyte Corporation as a collaborator. Results were first posted on 2026-11-16, following actual primary completion on 2025-09-30. The trial's overall status is active not recruiting, with enrollment of 30 participants (actual)1. The primary endpoint is complete response, defined as complete absence of any stage bladder tumor on post-treatment TURBT and no evidence of recurrent urothelial carcinoma on post-treatment urine cytology1.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.